NASDAQ: BYSIBeyondspring Inc Stock
$1.65+0.04 (+2.48%)
Updated Jun 24, 2026
BYSI Price
$1.65
Fair Value Price
$0.18
Market Cap
$67.64M
52 Week Low
$1.18
52 Week High
$2.62
P/E
-9.14x
P/B
-1.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.41
Operating Cash Flow
-$19M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BYSI Overview
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BYSI's potential to beat the market
- BYSI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BYSI news, forecast changes, insider trades & much more!
BYSI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BYSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BYSI ($1.65) is overvalued by 790.28% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BYSI ($1.65) is not significantly undervalued (790.28%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BYSI due diligence checks available for Premium users.
Valuation
BYSI fair value
Fair Value of BYSI stock based on Discounted Cash Flow (DCF)
Price
$1.65
Fair Value
$0.18
Overvalued by
792.99%
BYSI ($1.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BYSI ($1.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BYSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.14x
Industry
15.33x
Market
7.39x
BYSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.96x
Industry
5.21x
BYSI's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
BYSI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.4M
Liabilities
$48.8M
Debt to equity
-1.41
BYSI's short-term assets ($13.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYSI's long-term liabilities ($36.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$4.5M
Financing
-$4.2M
BYSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BYSI vs Biotech Stocks
Beyondspring Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.